-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Continued investment in research and development (R&D) by Pharmaceutical Research and Manufacturing Association (PhRMA) member companies has resulted in a plethora of new medicines that are transforming human healt.
Continued investment in research and development (R&D) by Pharmaceutical Research and Manufacturing Association (PhRMA) member companies has resulted in a plethora of new medicines that are transforming human healt.
PhRMA member companies have invested $103 billion in R&D in 2021, the highest level of investment on record In 2021, approximately $1 of every $5 in revenue will be invested in R&D
Over the past 20 years, PhRMA member companies have invested more than $1 trillion in new drug research and developmen.
Over the past 20 years, PhRMA member companies have invested more than $1 trillion in new drug research and development
Biopharmaceutical companies are at the heart of a robust R&D ecosystem that develops innovative treatments for patients:
In 2021 alone, the FDA's Center for Drug Evaluation and Research (CDER) has approved 50 new drug.
Even after a drug has been approved by the FDA, continued R&D often leads to the development of new uses for the drug, including early-stage treatment of the disease, new formulations that help make the drug easier to take, for different patient populations, such as As a pediatric population, or a completely different disease or conditio.
Continued R&D often leads to the development of new uses for drugs, including early-stage treatment, new formulations that help make drugs easier to take, for different patient populations, for example as a pediatric population, or for completely different diseases or condition
Since 2000, nearly 900 new drugs have been approved by the FDA to help patients live longer and improve their healt.
Since 2000, nearly 900 new drugs have received FDA approval; the first gene therapy for a devastating rare genetic disease affecting infants and children; a curative treatment for hepatitis C; CAR-T cell therapy, as well as immunotherapy and targeted therapy
Recent reports indicate that a significant amount of research and development is devoted to addressing unmet medical needs, including more than 500 drugs for the treatment of blood diseases, including blood cancer.
